The Austrian Center of Industrial Biotechnology (acib) has published research in Scientific Reports describing less common coronavirus mutations which could be of significance for researchers.
The mutations result in stronger binding to human cell receptors, and the group believes this could result in a potentially higher infection rate.
The S477G variant, which first appeared in Vienna, is now found in eight countries, with more than 27,000 people worldwide having been infected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze